Accelerating the Development and Improving Access to CAR and TCR engineered T cell therapy
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875171.
January 2021 - December 2025 (5 years)
UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUSMAXIMILIANS- UNIVERSITAT (UKW), GERMANYVIEW PARTNERS >
Academisch Medisch Centrum Bij De Universiteit Van Amsterdam (AMC), Netherlands
Bayer Aktiengesellschaft (Bayer), Germany
Biosci Consulting Bvba (Biosci), Belgium
Bundesinstitut Fur Impfstoffe Und Biomedizinische Arzneimittel (PEI), Germany
Consorci Institut D’investigacions Biomediques August Pi I Sunyer (Idibaps), Spain
Erasmus Universiteit Rotterdam (Eshpm), Netherlands
European Cancer Patient Coalition (ECPC), Belgium
Forschung E.V. (Fraunhofer), Germany
Fraunhofer Gesellschaft Zur Foerderung Der Angewandten
Fundacio Privada Institut De Recerca De L’hospital De La Santa Creu I Sant Pau (Ir-Hscsp), Spain
Information Technology For Translational Medicine (ITTM) Sa (ITTM), Luxembourg
Institut National De La Sante Et De La Recherche Medicale (INSERM), France
Institut National Du Cancer Gip, France
Janssen Pharmaceutica Nv (Janssen), Belgium
Medizinische Universitaet Wien (MUW), Austria
Miltenyi Biotec Bv & Co Kg (Mb), Germany
Ospedale Pediatrico Bambino Gesu (OPBG), Italy
T-Curx Gmbh (T-Curx) Germany
Technische Universitaet Muenchen (Tum), Germany
Universidad De Navarra (UNAV), Spain
Universita Vita-Salute San Raffaele (USR), Italy
University College London (UCL), UK
This project is funded by the European Union.
Why it matters
The aim of the project T2EVOLVE is to build a sustainable innovation ecosystem that will support the development of advance engineered T cell therapy to a level where every European cancer patient in need has access to safe and effective T cell products. How? The optimization of preclinical models, analytical monitoring, lymphodepletion regimens will enhance the development of safer and more effective engineered T cell therapies by reducing the toxicity observed in clinical trials and improve the success rate of clinical trials. A strategic aim of the project is to take an advantage on the tremendous potential that exists in Europe and close the gap in clinical and commercial translation in order to bring the EU back to the forefront of this global movement.
What ECPC does
ECPC will assist the T2EVOLVE project by engaging in patient involvement in the R&D process, co-development of patient friendly communication tools to improve the patient journey (M4-60)
co-development of tools and materials to help HCPs better respond to patient needs, patient-centered Health Technology Assessment of engineered T cell therapy and the creation of a roadmap for engineered T-cell therapy (online white paper).